As part of the partnership, Catapult Learning was named a select provider of professional development and coaching services to ensure that educators across the country are equipped to effectively ...
Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...
Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.
Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third quarter powered by the launch of its Farapulse system for atrial ...
Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...
Boston Scientific (NYSE: BSX) + today reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance again. The company’s CEO also said on its third ...
Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...
Boston Scientific is launching the Farawave Nav ablation catheter and Faraview software to treat atrial fibrillation in the U.S. · MedTech Dive · Courtesy of Boston Scientific Boston Scientific ...